skip navigationU S P T O SealUnited States Patent and Trademark Office AOTW logo
Home|Site Index|Search|Guides|Contacts|eBusiness|eBiz alerts|News|Help
Assignments on the Web > Patent Query
Patent Assignment Abstract of Title
NOTE:Results display only for issued patents and published applications. For pending or abandoned applications please consult USPTO staff.

Total Assignments: 3
Patent #:
NONE
Issue Dt:
Application #:
10482689
Filing Dt:
07/23/2004
Publication #:
Pub Dt:
12/30/2004
Inventors:
Eiichi Tanaka, Naoyuki Kamatani
Title:
METHOD FOR EVALUATING THE RISK OF ADVERSE EFFECTS OF THERAPEUTIC AGENTS FOR RHEUMATOID ARTHIRITIS (RA)
Assignment: 1
Reel/Frame:
015710/0433Recorded: 02/11/2005Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
02/19/2004
Exec Dt:
02/14/2004
Assignee:
JOWARE HANZOUMON BLDG. 2F. 2-19
HAYABUSA-CHO, CHIYODA-KU
TOKYO, JAPAN 102-0092
Correspondent:
STERNE KESSLER, GOLDSTEIN & FOX, PLLC
C/O JYOTI LYER
1100 NEW YORK AVENUE, NW
WASHINGTON, D.C. 20005-3934
Assignment: 2
Reel/Frame:
015754/0345Recorded: 07/23/2004Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignors:
Exec Dt:
02/19/2004
Exec Dt:
02/14/2004
Assignee:
JOWARE HANZOUMON BLDG. 2F, 2-19, HAYABUSA-CHO
CHIYODA-KU
TOKYO, JAPAN 102-0092
Correspondent:
STERNE KESSLER, GOLDSTEIN & FOX P.L.L.C.
C/O JYOTI IYER
1100 NEW YORK AVENUE, N.W.
WASHINGTON, D.C. 20005-3934
Assignment: 3
Reel/Frame:
015518/0264Recorded: 01/05/2005Pages: 3
Conveyance:
ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).
Assignor:
Exec Dt:
08/18/2004
Assignee:
5-9-22-101 SHINDEN, ICHIKAWA-SHI
CHIBA, JAPAN 272-0035
Correspondent:
STERNE, KESSLER, GOLDSTEIN & FOX PLLC
1100 NEW YORK AVE
WASHINGTON, DC 20005-3934

Search Results as of: 05/04/2024 10:24 PM
If you have any comments or questions concerning the data displayed, contact PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified: August 25, 2017 v.2.6
| .HOME | INDEX| SEARCH | eBUSINESS | CONTACT US | PRIVACY STATEMENT